©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Aug 26, 2015; 7(8): 449-453
Published online Aug 26, 2015. doi: 10.4330/wjc.v7.i8.449
Published online Aug 26, 2015. doi: 10.4330/wjc.v7.i8.449
Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors?
Jumana Saleh, Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat 123, Oman
Author contributions: The editorial was written by the author stated.
Conflict-of-interest statement: No conflict of interest is declared in this invited editorial manuscript.
Correspondence to: Dr. Jumana Saleh, Department of Biochemistry, College of Medicine and Health Sciences, Sultan Qaboos University, PO Box 35, Muscat 123, Oman. jumana@squ.edu.om
Telephone: +968-24-143534
Received: February 4, 2015
Peer-review started: February 5, 2015
First decision: April 27, 2015
Revised: May 21, 2015
Accepted: June 9, 2015
Article in press: June 11, 2015
Published online: August 26, 2015
Processing time: 204 Days and 6.9 Hours
Peer-review started: February 5, 2015
First decision: April 27, 2015
Revised: May 21, 2015
Accepted: June 9, 2015
Article in press: June 11, 2015
Published online: August 26, 2015
Processing time: 204 Days and 6.9 Hours
Core Tip
Core tip: Glycated hemoglobin is a useful marker for the diagnosis of diabetes progression. Many studies present glycated haemoglobin (HbA1C) as an independent predictor of cardiovascular risk in diabetics. Although haemoglobin (Hb) is a major circulating protein, limited information is available about the role of glycated Hb as such in the etiology of atherosclerosis. This editorial highlights potential mechanisms by which glycated hemoglobin may contribute, as a causative factor, to the progression of atherosclerosis in diabetics.